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Background: Recurrent protracted bacterial bronchitis (PBB), chronic suppurative lung disease (CSLD) and
bronchiectasis are characterised by a chronic wet cough and are important causes of childhood respiratory
morbidity globally. Haemophilus influenzae and Streptococcus pneumoniae are the most commonly associated
pathogens. As respiratory exacerbations impair quality of life and may be associated with disease progression, we
will determine if the novel 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
reduces exacerbations in these children.
Methods: A multi-centre, parallel group, double-blind, randomised controlled trial in tertiary paediatric centres from
three Australian cities is planned. Two hundred six children aged 18 months to 14 years with recurrent PBB, CSLD
or bronchiectasis will be randomised to receive either two doses of PHiD-CV or control meningococcal (ACYW135)
conjugate vaccine 2 months apart and followed for 12 months after the second vaccine dose. Randomisation will
be stratified by site, age (<6 years and ≥6 years) and aetiology (recurrent PBB or CSLD/bronchiectasis). Clinical
histories, respiratory status (including spirometry in children aged ≥6 years), nasopharyngeal and saliva swabs, and
serum will be collected at baseline and at 2, 3, 8 and 14 months post-enrolment. Local and systemic reactions will
be recorded on daily diaries for 7 and 30 days, respectively, following each vaccine dose and serious adverse events
monitored throughout the trial. Fortnightly, parental contact will help record respiratory exacerbations. The primary
outcome is the incidence of respiratory exacerbations in the 12 months following the second vaccine dose.
Secondary outcomes include: nasopharyngeal carriage of H. influenzae and S. pneumoniae vaccine and
vaccine- related serotypes; systemic and mucosal immune responses to H. influenzae proteins and S. pneumoniae
vaccine and vaccine-related serotypes; impact upon lung function in children aged ≥6 years; and vaccine safety.
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Discussion: As H. influenzae is the most common bacterial pathogen associated with these chronic respiratory
diseases in children, a novel pneumococcal conjugate vaccine that also impacts upon H. influenzae and helps
prevent respiratory exacerbations would assist clinical management with potential short- and long-term health
benefits. Our study will be the first to assess vaccine efficacy targeting H. influenzae in children with recurrent PBB,
CSLD and bronchiectasis.
Trial registration: Australia and New Zealand Clinical Trials Registry (ANZCTR) number: ACTRN12612000034831.
Keywords: Bronchiectasis, Child, Chronic suppurative lung disease, Non-typeable Haemophilus influenzae,
Pneumococcal conjugate vaccines, Protracted bacterial bronchitis, Randomised controlled trial, Respiratory
exacerbations, Streptococcus pneumoniaeBackground
Cough is the most common symptom reported for new
presentations to primary health care services interna-
tionally, [1] and in Australia accounts for 6.8% of family
medical practitioner consultations [2]. Chronic cough (>4
weeks duration) [3] in children is associated with increased
morbidity and often an unrecognised social and economic
burden upon the family and hidden costs for the health
care system [4]. There are many causes of chronic cough,
but amongst children with a persistent wet cough indicat-
ing the presence of excessive airway mucus, there is a sub-
set that has a spectrum of chronic pulmonary diseases.
These particular children, if left untreated may develop ir-
reversible airway injury, an event that was well recognised
in the pre-antibiotic era [5]. These disorders, protracted
bacterial bronchitis (PBB), chronic suppurative lung disease
(CSLD) and bronchiectasis, have in common impaired
mucociliary clearance, bacterial infection and lower airway
inflammation, features consistent with the ‘vicious circle
hypothesis’ for the pathogenesis of bronchiectasis [6]. PBB
is the most common of these entities, occurring predomin-
antly in preschool children [7,8]. It is characterised by an
isolated chronic wet cough without an alternative cause,
such as cystic fibrosis (CF) or immunodeficiency being
present, which resolves promptly with a two to four-week
course of antibiotics [9] In contrast, bronchiectasis is de-
fined as abnormal, irreversible bronchial dilatation and is
usually diagnosed by chest high-resolution computed tom-
ography (cHRCT) scans [10,11]. Children with bronchiec-
tasis have a chronic wet cough that responds slowly or
incompletely to antibiotic therapy. They also have recur-
rent lower respiratory infections and can develop add-
itional respiratory symptoms and signs [12]. Bronchiectasis
is either idiopathic or results from underlying systemic or
local pulmonary diseases predisposing to chronic en-
dobronchial infection. Between these two extremes are
children with CLSD who have the clinical features of bron-
chiectasis, but lack the supporting cHRCT evidence [10].
Recurrent (at least four) episodes of PBB may occur [1],
and if these no longer respond promptly to antibiotics,
underlying CSLD or bronchiectasis should be considered.There is a direct relationship between lower airway bac-
terial load and systemic and lower airway inflammation,
risk of acute respiratory exacerbations and quality of life
measures in adults with bronchiectasis [13]. Haemophilus
influenzae (usually unencapsulated or non-typeable (NTHi)
strains) is consistently the predominant pathogen found in
the sputum of adults with bronchiectasis [14] and chronic
obstructive pulmonary disease (COPD) [15-17]. It is also
the most common bacterial pathogen isolated from the
lower airways of children with PBB, CSLD or bronchiec-
tasis, followed less often by Streptococcus pneumoniae
(pneumococcus) and Moraxella catarrhalis [18,19]. Fur-
thermore, acquiring new H. influenzae strains can lead to
exacerbations in adults with COPD [15,20,21]. Acute
exacerbations are also important in bronchiectasis as they
are associated with lower quality of life (QoL) scores
[22,23] and poorer long-term outcomes. In adults with
bronchiectasis, the frequency of exacerbations, increased
systemic inflammatory markers and Pseudomonas aeru
ginosa infection are each determinants of an accelerated
pulmonary decline [24]. Amongst other factors, an in-
creased mortality risk is associated with the degree of lung
function impairment [25]. In children with bronchiectasis,
no prospective study exists, but the only significant pre-
dictor of pulmonary decline found in one retrospective
study was the frequency of hospitalised exacerbations
[26].
While pneumococcal polysaccharide and protein con-
jugate vaccines seem to have had little impact on the in-
cidence of these chronic pulmonary diseases [8,27],
interventions targeting H. influenzae may be more suc-
cessful in reducing exacerbations and leading to im-
proved clinical outcomes. Indeed, adult studies provide
“proof of concept” that a H. influenzae vaccine may be
beneficial. A systematic review of six randomised con-
trolled trials (RCT; 440 patients) reported oral mono-
bacterial whole-cell, killed H. influenzae vaccine reduced
the incidence of “bronchitis” episodes at three months
(rate ratio 0.69; 95% confidence interval (CI) 0.41, 1.14)
and six months after vaccination (rate ratio 0.82; 95% CI
0.62, 1.09) [28].
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to date have not been tested in children. Although very
different to a whole cell oral vaccine whole cell, oral
vaccine, the only vaccine available for children at present
that may impact upon H. influenzae infection is the paren-
teral 10-valent pneumococcal-H. influenzae protein D
conjugate vaccine (PHiD-CV; Synflorix®, GlaxoSmithKline
Biologicals, Rixensart, Belgium). The protein D (PD) com-
ponent is an outer membrane lipoprotein, which is anti-
genically conserved, surface located and present in most
H. influenzae (encapsulated and NTHi) strains [29]. It is
one of three H. influenzae proteins (PD, P6 and OMP26)
that have been the focus of potential vaccine antigens for
both adults and children in recent years [30,31], with PD
and P6 showing the most promise. Vaccine-induced anti-
PD antibodies have been associated with protective effi-
cacy against H. influenzae infection in middle ear and
pulmonary clearance in rat disease models [32]. A RCT
of an 11-valent prototype for PHiD-CV (Pneumococcal
Otitis Efficacy Trial (POET)) where children had
tympanocentesis during their first episode of acute otitis
media (AOM) found that the vaccine reduced the overall
incidence of AOM by 34%, including a 35% reduction in
H. influenzae-related cases [33].
However, since our trial commenced, data have been
published from a trial of PHiD-CV in 780 Dutch children
[34], and GlaxoSmithKline has made aggregate data from
a large trial of the vaccine in Latin American infants
(COMPAS) publicly available [35]. In the Dutch study
[34], infants received the vaccine at 2, 3, 4 and 11 to 13
months of age. Although the study found a lack of vaccine
efficacy (VE) against H. influenzae (principally NTHi)
nasopharyngeal colonisation (VE: 0.5%, 95% CI, -21.8%,
18.4%) and acquisition (VE: 10.9%, 95% CI, -31.3%, 38.9%)
no disease endpoints were reported. In COMPAS, vaccine
was administered at 2, 4, 6 and 12 to 15 months of age
and, despite inducing high serum anti-PD antibody levels,
no reduction in H. influenzae nasopharyngeal carriage was
observed at each three-monthly time point following the
third dose of vaccine up until the study ceased when chil-
dren reached two years of age [35]. There was a marginal
effect on any clinically confirmed AOM (VE 16.1%, 95%
CI −1.1, 30.4), but none observed for H. influenzae con-
firmed AOM (VE 15%, 95% CI −83.8, 60.7).
The data from COMPAS are difficult to interpret given
a surprisingly low prevalence of H. influenzae nasopharyn-
geal carriage in all children at each time point (approxi-
mately 5%), and that carriage data were only obtained in a
subset of children from a single participating centre (n =
2,000). Furthermore, of all clinically confirmed AOM epi-
sodes (n = 243), H. influenzae was only detected in 26
(10.7%), of which all were confirmed as NTHi. Hence,
there is a clear lack of study power to address the clinical
efficacy of the vaccine. The implications of these findings[34] and those of the Dutch study for older children, par-
ticularly those with chronic respiratory disease, need to be
established and more studies are required in different pop-
ulations with differing H. influenzae epidemiology to con-
firm vaccine efficacy.
Thus, our trial aims to determine whether respiratory
exacerbations in children with recurrent PBB, CSLD and
bronchiectasis can be reduced by PHiD-CV vaccination.Objectives of the study
Our primary objective is to determine the clinical efficacy
of PHiD-CV in reducing respiratory exacerbations in chil-
dren aged 18 months to 14 years with recurrent PBB,
CSLD or bronchiectasis.
Our secondary objectives are:
1. To evaluate the impact of a PHiD-CV vaccine on
nasopharyngeal carriage and bacterial load of H.
influenzae and pneumococcal vaccine-type and
vaccine-related serotypes at 2 months post-vaccine
dose 1 and then at 1, 6 and 12 months following the
second vaccine dose in children with recurrent PBB,
CSLD or bronchiectasis.
2. To evaluate the systemic and mucosal immune
responses to PD and non-vaccine type H. influenzae
proteins (P4, P6) and PHiD-CV pneumococcal
vaccine and vaccine-related serotypes at 2 months
post-dose 1, and then at 1, 6 and 12 months
following the second vaccine dose in children with
recurrent PBB, CSLD or bronchiectasis.
3. To determine the effect of PHiD-CV vaccine on
lung function in children with recurrent PBB, CSLD
and bronchiectasis.
4. To evaluate the safety of PHiD-CV vaccine and
meningococcal (ACYW135) conjugate vaccine in
children with recurrent PBB, CSLD or
bronchiectasis.
Our study tests the primary hypothesis that amongst
children aged 18 months to 14 years with PBB, CSLD or
bronchiectasis, vaccination with PHiD-CV reduces the
incidence of respiratory exacerbations in the 12 months
following two doses of vaccine compared to children
who received the control (meningococcal ACYW135
Sanofi Pasteur, Lyon, France) conjugate vaccine.Methods
Study design
This is a multicentre, parallel-group, double-blind RCT
(with concealed allocation) to assess the efficacy of PHiD-
CV in reducing respiratory exacerbations in children with
recurrent PBB, CSLD and bronchiectasis. The study plan
is summarised in the figure.
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Inclusion criteria are:
1. Aged 18 months to 14 years inclusive with recurrent
PBB, CSLD or bronchiectasis.
2. Receipt of meningococcal C conjugate vaccine at
least six months before enrolment;
3. Negative urine pregnancy test if post-menarchal
female.
4. Provision of written informed consent from parent/
guardian (assent if child aged ≥10 years).
5. Parent/child willing and able to meet the
requirements of the protocol.
6. Access to a telephone and not planning to move
from the study area in the 14 months post-
enrolment.
7. Has experienced two or more respiratory
exacerbations in the 18 months prior to study entry.
Exclusion criteria are: chronic lung conditions other
than co-existent asthma and those under investigation in
this study; prior vaccination with PHiD-CV vaccine;
received the 23-valent pneumococcal polysaccharide vac-
cine (Pneumovax-23, Commonwealth Serum Laboratories
Biotherapies, Melbourne, Victoria, Australia) within the
previous two months; contraindication/known hypersensi-
tivity to PHiD-CV and/or quadrivalent (ACYW135) menin-
gococcal conjugate vaccine; immunosuppressive condition
or immunodeficiency disorder that may influence respon-
ses to vaccines; systemic immunosuppressive therapy; ad-
ministration of immunoglobulins and/or blood products
within 90 days of receiving study vaccine; active participa-
tion in a clinical trial of another investigational drug/
vaccine or therapy; acute illness at the time of enrolment,
and other medical conditions that could increase the risk
of serious adverse events (SAEs) from being in the study.
Recruitment
Eligible children will be identified from specialist respira-
tory clinics in tertiary paediatric hospitals in Brisbane,
Perth and Sydney, Australia. Parents will be ap-
proached by study personnel and informed consent/
assent obtained.
Intervention, follow-up and data collection
Children will be randomised (1:1 allocation) to receive ei-
ther PHiD-CV or meningococcal (ACYW135) conjugate
vaccine. Following baseline assessment of their general
medical history, respiratory status (including spirometry
for children aged ≥6 years), concomitant medication use
and vaccination history, children will receive two vaccine
doses, 2 months apart, and followed for 12 months post
the second vaccine dose. Follow-up includes: three further
clinical visits (1, 6 and 12 months post-dose-2); fortnightlytelephone interviews with parents to monitor respiratory
status; local and systemic adverse event monitoring using
parent-completed daily diary cards for 7 and 30 days, re-
spectively, after each vaccine dose; and surveillance for
SAEs for the entire study period. All data will be recorded
on standardised forms. The primary and secondary out-
come measures are collected at the time points specified
in Figure 1.
A respiratory exacerbation is defined as an increase in
sputum volume or purulence, or three or more days of
change in cough (>20% increase in cough score or type
(dry to wet)). This definition has been validated, with ex-
cellent kappa values between senior clinicians (>0.75) for
these symptoms and signs [26]. In addition to active sur-
veillance, parents will be trained in recognising the fea-
tures of an exacerbation and asked to report any potential
episodes that are not captured during the fortnightly
follow-up contacts.
Randomisation, allocation and blinding
An independent biostatistician prepared the randomisa-
tion code using a permuted blocking design (block size of
four) to maintain group balance. Randomisation was
stratified by site, age (less than six years and six or more
years), and PBB vs CSLD/bronchiectasis. The age of six
years was chosen as at this age spirometry can be
performed reliably in children. Treatment allocation is de-
termined by the trial pharmacist at the Royal Children’s
Hospital, Brisbane based on the randomisation list pro-
vided by the independent statistician. At the time of ran-
domisation, the child’s study specific stratum is confirmed
and a request for randomisation based on that stratum is
provided to the pharmacist. The trial pharmacist selects
the next consecutively numbered opaque sealed envelope
from the relevant strata pack, opens the envelope and ex-
tracts the randomisation code. This is checked against the
randomisation list and a vaccine pack matching the alloca-
tion code is assigned to the participant. The allocation se-
quence is concealed at all times throughout the study
from all blinded investigators, study staff and participants.
Since the vaccines differ in colour, their preparation
and delivery will be performed by nurses at each partici-
pating centre who are independent of the study.
Unblinding of individual participants will only occur in
emergency situations and ideally after discussion with
the Data Safety Monitoring Committee (DSMC). The
randomisation code will be unblinded once the database
is locked and the data analysed.
Specimen collection
All children will have nasopharyngeal swabs, saliva and
serum collected at enrolment and at 2 months post-
vaccine dose 1, and then at 1, 6 and 12 months following
the second study vaccine dose (Figure 1). Nasopharyngeal
Figure 1 Overall schematic study plan.
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World Health Organization (WHO) Guidelines [36] and
placed in 1.0 ml of skim-milk-tryptone-glucose-glycerol
broth. Saliva will be collected using large cotton-tipped
swabs, which when soaked are put in a 15 ml tube and
placed immediately on ice, while serum will be separated
into multiple aliquots. All three specimen types from each
child will be stored at local laboratories at −80°C before
being transported frozen to the research laboratories.
Laboratory methods
Nasopharyngeal swabs
Batches of swabs will be thawed and 10 μL aliquots cul-
tured overnight on selective media at 37°C in 5% CO2. H.
influenzae and S. pneumoniae will be confirmed by
standard techniques and routine susceptibility testing
performed using the calibrated dichotomous susceptibility
disc diffusion method [37]. Diversity of H. influenzae iso-
lates will be determined by polymerase chain reaction
(PCR)-ribotyping, while the Quellung method (antisera
from Statens Serum Institute, Copenhagen, Denmark) will
be used to serotype pneumococcal isolates [38].
Real-time quantitative PCR assays will be used to esti-
mate H. influenzae and S. pneumoniae loads in nasopha-
ryngeal specimens using an in-house multiplex assay. The
H. influenzae target is hpd [39], which also helps differen-
tiate between H. influenzae and the commensal H.
haemolyticus, while the target for S. pneumoniae is lytA
[40]. Quantitative standards will be generated from the
reference strains S. pneumoniae (ATCC 49619) and H.
influenzae (ATCC 19418) obtained from the American
Type Culture Collection.
Saliva swabs
Saliva antibodies will be measured against purified H.
influenzae (PD, P4 and P6) and pneumococcal (CbpA,
PspA1 + 2 and pneumolysin) proteins and pneumococcalvaccine serotype (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) and
serotype-related (6A, 19A) polysaccharides using a multi-
plex bead assay [41]. Polysaccharide antigens will be con-
jugated to poly-L-lysine (Sigma Aldrich, Castle Hill, NSW,
Australia) using a two-step carbodiimide reaction. All
antigens will be covalently bound to carboxylated
microspheres (Bio-Rad Laboratories, Gladesville, NSW,
Australia) of a specific fluorescent region. Saliva will be di-
luted in adsorption buffer (phosphate buffered saline
(PBS) 0.05% Tween 20 and 2% calf serum; Sigma Aldrich),
pneumococcal cell wall polysaccharide (Statens Serum In-
stitute, Copenhagen, Denmark) and serotype 22F polysac-
charide (American Type Culture Collection, Manassas,
VA, USA) for the polysaccharide assays and straight ad-
sorption buffer for protein assays. Diluted samples will be
incubated with antigen-conjugated microspheres at room
temperature then washed (PBS 0.05% Tween 20). For de-
tection of IgG or IgA, R-phycoerythrin conjugated anti-
human IgG or IgA (Jackson ImmunoResearch Laborator-
ies, West Grove, PA, USA), respectively, will be used. The
fluorescence in each specific bead region will be measured
using the BioPlex® 200 System (Bio-Rad Laboratories).
Data will be acquired electronically in real-time and
analysed using Bio-plex Manager 5.0 software.
Serum samples
Serum antibodies will be measured against purified H.
influenzae and pneumococcal proteins and pneumococcal
polysaccharides outlined above using a multiplex bead
assay as described previously [42].
To supplement pneumococcal multiplex bead assays,
multiplex opsonophagocytic killing assays will be performed
according to the protocol of the WHO Reference La-
boratory for pneumococcal serology at the University of
Alabama. Only serum from children who have not taken
antibiotics within three days of venesection will be
tested. Briefly, serially diluted serum samples will be
O’Grady et al. Trials 2013, 14:282 Page 6 of 11
http://www.trialsjournal.com/content/14/1/282incubated with four pneumococcal serotypes, each with
different antibiotic susceptibilities, for 30 minutes at
room temperature on an orbital shaker. Samples will be
incubated with both rabbit complement and HL-60 cells
at 37°C with 5% CO2 for 45 minutes. Following incuba-
tion, phagocytosis will be stopped by placing microtitre
plates on ice for 20 minutes. The reaction mixture will be
spotted onto Todd-Hewitt Yeast Agar plates and the mix-
ture left to absorb into the agar for 20 minutes at room
temperature. The antibiotic (either optochin, spectino-
mycin, trimethoprim or streptomycin) containing overlay
will be added to each of the plates and incubated at room
temperature for 20 minutes. Plates will then be incubated
upside down in a candle car for 16 to 18 hours at 37°C.
Colonies will be counted by an automatic colony counter
and data analysed using the Opsotitre 3 software (Univer-
sity of Alabama, Birmingham, Alabama, USA). Opsonisa-
tion indices will be calculated using linear interpolation of
the serum dilution killing 50% of bacteria.Lung function
Lung function in children aged six or more years will be
measured with a standard spirometer using American
Thoracic Society criteria at enrolment and 6 and 12
months following the second vaccine dose.End points
Participation is completed 12 months (± 14 days) follow-
ing the second vaccine dose. Other exit points are serious
protocol violations and SAEs deemed by the treating clin-
ician or the DSMC to be associated with the study vac-
cine. Children meeting the exit criteria will continue to be
followed until the end of the trial period.Outcome measures
Primary outcome
The incidence of respiratory exacerbations in the 12
months following the second vaccine dose.Secondary laboratory outcomes
Nasopharyngeal carriage and load of H. influenzae and
S. pneumoniae and systemic and mucosal immunity to
H. influenzae proteins (PD, P4, P6) and PHiD-CV
pneumococcal vaccine-type and vaccine-related sero-
types at 2 months post-dose 1, and then at 1, 6 and 12
months following the second vaccine dose.Secondary lung function outcomes
Spirometry at enrolment and 6 and 12 months after the
second vaccine dose.Secondary safety outcomes
Local injection site and systemic reactions in the 7 and 30
days following each vaccine dose, respectively, and SAEs
throughout the entire study period.
Sample size
Prospective data collected in Brisbane children with non-
CF bronchiectasis indicate a mean annual incidence of 2.1
(standard deviation 1.046) exacerbations requiring hos-
pital clinic attendance or hospitalisation. PHiD-CV effi-
cacy against exacerbations in children with bronchiectasis
is unknown. However, based on the aforementioned pilot
data and AOM data from the POET study (30% reduction)
[33], our trial is powered to detect a 30% reduction from
2.1 to 1.47 exacerbations in the 12 months following the
second vaccine dose. Assuming a Poisson distribution, 93
children per group will provide 90% power (α = 0.05, two-
sided) to detect a 30% reduction in exacerbations in the
PHiD-CV group and 80% power to detect a 25% reduc-
tion. Assuming a 10% loss to follow-up, we will recruit
206 children (103 per group). Differences of less than 20%
are unlikely to change clinical practice without additional
supporting evidence.
Analysis
Data will be presented in accordance with the updated
CONSORT criteria [43]. Demographic data will be tabu-
lated and expressed as proportions and/or means of the
selected characteristics by vaccine group with the corre-
sponding 95% confidence intervals. Differences between
groups will be assessed by the normal test for comparisons
of means and χ2 tests for comparison of proportions.
The primary analysis will assume a Poisson distribution
and will compare the incidence of respiratory exacerba-
tions between the two groups. Vaccine efficacy (VE) (%)
will be calculated as (1 – Relative Risk (RR))*100 where
RR represents the ratio of the incidence of exacerbations
in the PHiD-CV group to the incidence in the control
group (and presented with its 95% CI). All analyses will be
performed on an intention-to-treat basis and will account
for baseline stratification.
Secondary analyses
The proportion of children with nasopharyngeal carriage
of H. influenzae and S. pneumoniae at each time point will
be compared between vaccine groups and presented as
RR and 95% CI, adjusted for repeated measures. VE (%)
against carriage will be calculated as (1-RR)*100 and
presented with its 95% CI. Bacterial load at each time
point will be compared.
Serum and mucosal antibody responses to H. influenzae
proteins, including PD, pneumococcal protein and poly-
saccharide antigens and opsonophagocytic killing assays:
geometric mean titres at each sampling time point will be
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(and 95% CI) from linear regression models. In addition,
the proportion of children assessed to be seropositive will
be compared between groups at each sampling time point
using χ2 tests for proportions and logistic regression
models to adjust for stratification. All differences will be
presented with their 95% CIs.
Safety and reactogenicity of vaccination: descriptive ana-
lyses will be performed on the number, type and severity
of local and systemic reactions and SAEs that occur fol-
lowing vaccination and presented by treatment group.
Comparisons between groups will be performed using
Student’s t-test for continuous variables and χ2 tests for
proportions.
Sub-group analyses will be performed for all primary
and secondary objectives to examine potential differences
by study specific strata. Univariate and multivariate ana-
lyses will be performed to evaluate variables independently
associated with study endpoints and to assess potential
confounding factors in the association between vaccin-
ation and disease.Data safety monitoring committee
A DSMC has been established and has met prior to com-
mencing this study. A priori stopping rules include:Efficacy
A Fleming-Harrington-O’Brien [44] stopping boundary
will be used at the interim analysis (described below),
with a nominal P-value required for significance of .001.
The final analysis will be referred to a nominal signifi-
cance level of .0497. An interim analysis of the primary
endpoint will be conducted after the first 126 subjects
have completed the 12-month follow-up post the second
vaccine dose. Sixty-three subjects per group will provide
80% power (α = 0.05, two-sided) to detect a reduction in
exacerbations of 30%. At this point, and in discussion
with the DSMC, a decision will be made with respect to
continuing recruitment based on both the statistical sig-
nificance and clinical relevance of any effect observed.Toxicity
During the trial, the occurrence of local or systemic
reactogenicity may occur at rates that justify additional
safety evaluations. If the conditions of any of the stop-
ping rules are satisfied, the data will be assessed fully by
the DSMC to determine that it is safe to continue the
study. A multi-stage early stopping design approach [45]
will be employed to define stopping rules after the oc-
currence of each observed SAE by comparing the total
number of patients included to the maximal number of
patients that satisfies maximal acceptable SAE criteria.Ethics approval
Human Research Ethics Committees of all the partici-
pating institutions have approved the study. It is being
conducted under Australia’s Therapeutic Goods Admin-
istration Clinical Trial Notification scheme. The Univer-
sity of Queensland is the trial sponsor.
Discussion
PBB, CSLD and bronchiectasis are important chronic
paediatric respiratory illnesses globally. Repeated respira-
tory exacerbations in those with bronchiectasis are asso-
ciated with significant long-term morbidity [25,46,47].
There is also historical precedent in the pre-antibiotic
era that children with recurrent or persistent wet cough
progressed from having normal radiographic appearance
to those consistent with bronchiectasis [5]. As H.
influenzae is the most common bacterial pathogen asso-
ciated with these diseases in adults and children [18,19],
a vaccine that could reduce or eliminate H. influenzae
may avert exacerbations and reduce antibiotic use. This
would be an important adjunct to current clinical man-
agement and may lead to short- and long-term health
benefits. Our study, therefore, has clinical efficacy as the
primary outcome and will be the first to assess the clin-
ical impact of vaccines targeting H. influenzae in chil-
dren with these diseases.
The systemic and mucosal immune responses, particu-
larly antibody functionality, to PHiD-CV in children
with recurrent PBB, CSLD and bronchiectasis have not
been examined previously. Our study will examine re-
sponses to not only PD, but related H. influenzae pro-
teins (P4 and P6) that have been considered as vaccine
candidates as well as assessing responses to S.
pneumoniae vaccine and vaccine-related serotype spe-
cific antigens. A prospective study of serum antibody re-
sponse to three different H. influenzae outer membrane
proteins (including PD) during episodes of AOM in
otitis-prone and non-otitis-prone children highlights the
importance of measuring immune responses in addition
to clinical endpoints [48]. It reported diminished IgG re-
sponses to these antigens in otitis-prone children com-
pared to non-otitis-prone children at the time of, and
following, an AOM episode. Increased susceptibility in
otitis-prone children might be related to suboptimal cir-
culating functional T-helper memory and reduced IgG
responses to H. influenzae or S. pneumoniae after colon-
isation and AOM [49]. These data support ongoing
evaluation of responses in children at high-risk of H.
influenzae infection.
Immunological responses to pneumococcal vaccine
antigens are important to evaluate because of recent
data suggesting diminished immunogenicity in children
who have had either multiple exposures to vaccine anti-
gens [50], or increased density of S. pneumoniae
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[51,52]. The clinical significance of these observations,
however, remains uncertain. A recent study has exam-
ined S. pneumoniae isolates from bronchoalveolar lavage
(BAL) cultures of children with chronic cough thought
to be due to PPB [53]. The results suggested significant
differences in serotype distribution between 7vPCV vac-
cinated and unvaccinated children, with immunised chil-
dren less likely to have vaccine serotypes isolated from
BAL cultures, but also more likely to have non-vaccine
serotypes than unimmunised children [53]. These find-
ings are consistent with our own observations where
pneumococcal conjugate vaccines appear to have had lit-
tle impact on the burden of lower respiratory tract dis-
ease in high-risk Indigenous Australian populations [54],
in whom S. pneumoniae isolates from nasopharyngeal
and BAL cultures are principally non-vaccine serotypes
[38,55]. Whether these differences resulted from host
responses or population-based changes in circulating
serotypes is unknown; however, the study suggests that
ongoing surveillance of S. pneumoniae in this patient
population is required.
It cannot be assumed that existing VE data against H.
influenzae nasopharyngeal carriage and clinical disease
(primarily AOM) in healthy young infants for PHiD-CV,
and its 11-valent prototype in POET, can be generalised to
preventing acute respiratory exacerbations in the lower
airways of older children with PBB, CSLD or bronchiec-
tasis. While the bacterial pathogens invading the middle
ear cavities and the lower respiratory tracts of these pa-
tients are similar, the bacterial clearance mechanisms and
immunity induced following a parenterally administered
vaccine may differ between the two anatomical sites. In
addition, a recent small study identified significantly re-
duced natural antibody levels to PD in adult patients with
COPD (without exacerbation at time of specimen collec-
tion) and secondary immunodeficiency disorders com-
pared to healthy controls, and that natural antibody levels
declined with age [56]. Suboptimal circulating functional
T-helper memory and reduced IgG responses to S.
pneumoniae or H. influenzae have also been identified in
otitis-prone children [49]. These data potentially indicate
deficient host responses to H. influenzae infection in
people with disease and that boosting antibody responses
with vaccines may be required. Similar data do not exist
for children with chronic lung diseases and, therefore, we
have commenced an add-on study to the current protocol
to examine this issue.
With respect to differences between nasopharyngeal
carriage and disease, the POET study demonstrated a re-
duction in AOM caused by H. influenzae, but not
nasopharygeal carriage by this organism in healthy chil-
dren up to two years of age [33]. However, that study is
not comparable to ours given the different population andprimary endpoints and, in addition, the vaccine used pos-
sessed a higher content of PD than the currently licensed
10-valent PHiD-CV. Furthermore, there remains the pos-
sibility of different strains and virulence factors operating
between colonisation and disease states [34]. Data com-
paring these factors between nasopharyngeal and lower
airway H. influenzae isolates in children with non-CF
bronchiectasis or other chronic lung diseases are virtually
non-existent. A small study conducted in Australian
Indigenous children [38], a population with extensive H.
influenzae acquisition very early in life [57] and excessive
rates of recurrent upper and lower respiratory tract infec-
tions [58], found a high density and diversity of respiratory
bacteria. It also found nasopharyngeal and BAL strain
concordance between the upper and lower airways in 45
children with HRCT confirmed bronchiectasis. However,
this study was not conducted at the time of an acute ex-
acerbation and 27 (60%) had received antibiotics within
two weeks of specimen collection [38].
Currently, data on PHiD-CV VE against H. influenzae
carriage and disease in older children are limited to the re-
sults from a single study involving healthy four-year-olds
[59]. This was a follow-up study of an earlier trial [60] of
the PHiD-CV in Czech children conducted when they
were 31 to 44 months of age. Persistence of NTHi naso-
pharyngeal carriage was a secondary objective. Thirty per-
cent of the original cohort (n = 686) did not participate in
the follow-up study. Children primed previously with
PHiD-CV received a fifth dose at 40 to 48 months of age,
the unprimed group received two doses of PHiD-CV two
months apart. Post-booster nasopharyngeal carriage data
at 24 to 27 months of age from the first study suggested a
VE against NTHi carriage of 51.2% (95% CI 11.7, 73.9).
However, carriage increased in vaccinees (from 8.5% to
33.5%) and controls (17.3% to 38.9%) at each time point
thereafter and, at ages of 31 to 44 months and 40 to 48
months, there was no difference between the two groups
[59]. Carriage data beyond those time points have not yet
been published.
In addition, the long-term impact of the vaccine on
carriage of other microbes is similarly limited. In the same
extension study of Czech children, there was no diffe-
rence between groups in Staphylococcus aureus and M.
catarrhalis carriage over the same time period [59]. This
provides an early, albeit insufficient, indication that the
PHiD-CV has not altered the dynamics of carriage of
these two organisms in healthy young children over time.
Whether the same findings occur in children with chronic
lung diseases is currently unknown, although we have the
capacity to examine these effects in additional laboratory
studies outside of the current protocol. Nonetheless,
replacement of vaccine type pneumococci by non-vaccine
type serotypes has been observed commonly in experimen-
tal and non-experimental studies of other pneumococcal
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carriage of S. aureus and H. influenzae has also been
reported [61,62].
The two study vaccines have well established safety pro-
files in young children. However, as they are being admin-
istered outside of licensed indications in Australia, and to
a population of children with existing morbidities, we will
undertake a complete safety evaluation during the trial.
Our safety endpoints are consistent with those used in tri-
als of both vaccines and SAE monitoring is consistent
with Good Clinical Practice criteria [63].
In summary, our RCT will be the first to examine the
impact of a vaccine targeting H. influenzae in children
with recurrent PBB, CSLD and bronchiectasis. The best
evidence to answer questions about strain concordance,
acquisition of new strains and subsequent infection in the
lower airways, and changes in the microbiological profile
of acute exacerbations in children with chronic lung dis-
eases following vaccination with PHiD-CV, are best
obtained if BALs are performed at baseline, at each study
time point and during acute exacerbations. This is ethic-
ally unacceptable and, hence, our choice of a clinical end-
point as the primary objective follows the concept of
vaccine probe studies as markers of disease burden [64],
as demonstrated previously in pneumococcal conjugate
and Hib vaccine trials. Clinical efficacy will be evaluated in
the context of detailed nasopharyngeal carriage, immuno-
genicity, lung function and safety data to provide a
detailed assessment of whether vaccines may reduce exac-
erbations and provide an opportunity to improve long-
term health outcomes. The study will also be an important
contribution to the literature on the effects of conjugate
vaccines on the nasopharyngeal microbiology of children
with recurrent PBB, CSLD and bronchiectasis.
Trial status
Recruitment began in January 2013.
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